---
title: "TARS.US (TARS.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/TARS.US/news.md"
symbol: "TARS.US"
name: "TARS.US"
parent: "https://longbridge.com/en/quote/TARS.US.md"
datetime: "2026-03-05T08:10:46.442Z"
locales:
  - [en](https://longbridge.com/en/quote/TARS.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/TARS.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/TARS.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/TARS.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/TARS.US/news.md)


# TARS.US (TARS.US) — Related News

### [Why Are Shares Of Xeris Biopharma Falling Friday?](https://longbridge.com/en/news/277234588.md)
*2026-02-27T17:29:00.000Z*
> Xeris Biopharma Holdings shares fell 10.83% to $6.01 after announcing a patent infringement lawsuit against Torrent Phar

### [Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit | XERS Stock News](https://longbridge.com/en/news/277111238.md)
*2026-02-26T14:55:00.000Z*
> Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) announced that its subsidiaries have filed a patent infringement lawsuit a

### [](https://longbridge.com/en/news/276743906.md)
*2026-02-23T21:48:21.000Z*
> Tarsus Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 sales results.

### [Tarsus Pharmaceuticals | 10-K: FY2025 Revenue Beats Estimate at USD 451.36 M](https://longbridge.com/en/news/276644777.md)
*2026-02-23T21:13:45.000Z*
### [Tarsus Pharmaceuticals | 8-K: FY2025 Revenue Beats Estimate at USD 451.36 M](https://longbridge.com/en/news/276644172.md)
*2026-02-23T21:09:43.000Z*